Loading...
Loading...
Monday, Johnson & Johnson JNJ announced longer-term data from Phase 1/2 MajesTEC-1 study of Tecvayli (teclistamab-cqyv) showing deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM). Results from the MajesTEC-1 study show that, at a median follow-up of 30.4 months, patients treated with Tecvayli at the recommended Phase 2 dose demonstrated an overall response rate (ORR) of 63%, with responses continuing to deepen and 46% of patients achieving a complete response (CR) or better.
For patients with a CR or better, median duration of response (mDOR), median progression-free survival (mPFS), and median overall survival (mOS) were not yet reached, and estimated 30-month DOR, PFS, and OS rates were 61%, 61% and 74%, respectively. The safety profile remained consistent, with a notable decrease in new onset of severe infections over time. Extended follow-up of patients from a MajesTEC-1 cohort, investigating the prophylactic use of tocilizumab for the reduction of cytokine release syndrome (CRS) in patients treated with Tecvayli, were also presented at ASCO.
Results show that a single dose of tocilizumab before Tecvayli in patients with RRMM (n=24) reduced the incidence of CRS with a 65% relative reduction versus the overall MajesTEC-1 population. This approach is continuing to be evaluated in the Phase 2 OPTec study of Tecvayli in the community setting. Data showed preliminary evidence that prophylactic tocilizumab potentiall.
